文献速递肾小球疾病慢性肾脏病

狼疮性肾炎患者长期使用他克莫司的肾脏与心血管风险

Long-term renal and cardiovascular risks of tacrolimus in patients with lupus nephritis.
PubMed 文献 · Nephrol Dial Transplant · 2024-01-01

这项观察性队列研究纳入219例成人狼疮性肾炎患者,其中43例(19.6%)接受他克莫司治疗,中位随访7.1年。他克莫司暴露与肾功能显著下降相关(6.8 vs 0.8 mL/min/1.73 m2),但终末期肾病发生率、心血管事件发生率与对照组相似;他克莫司组HbA1c更高(37.4 vs 33.6 mmol/mol),糖尿病发生率无差异。

要点

  • 他克莫司暴露与狼疮性肾炎患者长期肾功能下降相关,需警惕肾脏不良反应。
  • 他克莫司组心血管事件发生率与未暴露组同样低,高血压和血脂异常无差异。
  • 他克莫司组HbA1c更高,虽糖尿病发生率相似,仍应监测血糖代谢。

核心结论

  • 他克莫司暴露与狼疮性肾炎患者长期肾功能丧失相关,并可能增加糖尿病风险。

研究设计与样本

  • 观察性队列研究,纳入219例成人狼疮性肾炎患者,其中43例(19.6%)有他克莫司暴露,对照组为未使用钙调磷酸酶抑制剂的狼疮性肾炎患者。

主要发现

  • 中位随访7.1年,他克莫司组肾功能下降6.8 mL/min/1.73 m2,对照组下降0.8 mL/min/1.73 m2。
  • 终末期肾病发生率两组相似,心血管事件发生率两组均低。
  • 他克莫司组10年冠心病风险更低,主要归因于年龄差异。
  • 他克莫司组HbA1c为37.4 mmol/mol,高于对照组的33.6 mmol/mol,但糖尿病发生率相似。
  • 高血压和血脂异常发生率两组无差异。

临床怎么用

  • 对使用他克莫司的狼疮性肾炎患者应定期监测肾功能,警惕长期肾毒性。
  • 尽管心血管事件风险未增加,仍需关注血糖代谢,定期检测HbA1c。

局限性

  • 为观察性研究,可能存在混杂因素,他克莫司组与对照组在年龄等方面存在差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite continuous advancement, treatment of lupus nephritis (LN) remains challenging. Recent guidelines now include a regimen incorporating tacrolimus as a first-line treatment option. Even though tacrolimus is effective in combination with mycophenolate and corticosteroids, concerns remain regarding long-term use, given its association with increased cardiovascular risks including nephrotoxicity, hypertension, dyslipidemia and hyperglycemia in kidney transplant recipients. However, in LN, long-term evaluations and head-to-head comparisons are lacking and thus the safety profile remains ill-defined. We hypothesized that chronic toxicity also occurs in LN patients. Therefore, this study aimed to assess long-term cardiovascular and renal outcomes of tacrolimus in LN patients. METHODS: This observational cohort study examined adult LN patients treated with tacrolimus, assessing renal outcomes, hypertension, diabetes, dyslipidemia, cardiovascular events and the Framingham risk score. The results were compared with a control group of CNI-naïve LN patients. RESULTS: Of the 219 LN patients in this study, 43 (19.6%) had tacrolimus exposure. Over a median follow-up of 7.1 years, tacrolimus use was associated with significant kidney function decline (6.8 mL/min/1.73 m2, versus 0.8 in the control group). The incidence of end-stage kidney disease was similar. Cardiovascular event incidence was equally low in both groups. The 10-year risk of coronary heart disease was lower in the tacrolimus group, primarily due to age differences. HbA1c levels were higher in the tacrolimus group (37.4 mmol/mol) than in controls (33.6 mmol/mol), although the incidence of diabetes was similar. There were no differences in the occurrence of hypertension or dyslipidemia. CONCLUSIONS: Our study demonstrated that tacrolimus exposure was associated with long-term kidney function loss in LN patients. Although cardiovascular risk factors and events were similar to patients never exposed to tacrolimus, there may be an increased risk of developing diabetes. Therefore, our study supports vigilance towards renal adverse effects in LN patients treated with tacrolimus.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. van Schaik M, Bredewold OW, Priester M, et al. Long-term renal and cardiovascular risks of tacrolimus in patients with lupus nephritis. Nephrol Dial Transplant. 2024. PMID: 38769592. doi:10.1093/ndt/gfae113

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。